Pipeline

Global

Designated Regions in Asia-Pacific,
the Middle East and North Africa

Designated Asian Regions

Mainland China, Hong Kong, Macau and Taiwan

China

Overseas

Product	Rights Authorized Region *	Indication	Core/Mechanistic Advantages	Pre-clinical	Clinical Trial Approval	Phase I	Phase II	Phase III	Marketing Application	Marketed
											Ruxolitinib phosphate cream		Atopic dermatitis	The first topical JAK inhibitor approved by the U.S. FDA							(the U.S., the EU **)
Vecantoxatug Injection		Passive immunization against tetanus	Recombinant humanized anti-tetanus neurotoxin monoclonal antibody with superior efficacy to HTIG
Benzgalantamine Gluconate Enteric-coated Tablets (ZUNVEYL)	#	Alzheimer’s disease	The second oral therapy approved by the U.S. FDA for the treatment of Alzheimer’s disease in over a decade, demonstrating a potentially better gastrointestinal safety profile							(the U.S.)
Loberamisal for Injection (Y-3 for Injection)		Acute ischemic stroke	The world’s first multi-target brain cytoprotective agent targeting PSD95-nNOS and MPO, which achieved a 69.7% rate of excellent functional outcome at 90 days in patients with stroke, with the potential to simultaneously prevent post-stroke depression and anxiety
Comekibart Injection *** (MG-K10)		AD in adults	Expected to be the first long-acting (dosing once every four weeks) anti-IL-4Rα humanized monoclonal antibody approved in China
		Seasonal allergic rhinitis
		Asthma, prurigo nodularis, chronic spontaneous urticaria, AD in adolescents
		Chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease
ABP – 671	##	Gout and hyperuricemia	A next-generation, highly selective URAT1 inhibitor with higher target attainment rates, faster target attainment, and clear benefits in tophi dissolution, expected to become the preferred first-line urate-lowering therapy for patients with gout and hyperuricemia
Silevimig Injection		Passive immunization for rabies virus exposure in children aged 2 to <18 years	The world’s first fully human dual-epitope specific antibody against the rabies virus
Povorcitinib Phosphate Tablets (povorcitinib)		Hidradenitis suppurativa	A selective oral small-molecule JAK1 inhibitor, with the potential to provide a new treatment option for patients suffering from autoimmune and inflammatory dermatologic diseases
		Nonsegmental vitiligo
		Prurigo nodularis
TYK2 Inhibitor (CMS-D001)		Intended for psoriasis	Inhibiting the pathological processes of autoimmune diseases while reducing the impact on other JAK family kinases, potentially offering both efficacy and safety
		Intended for atopic dermatitis
		Intended for ulcerative colitis
		Intended for Crohn’s disease
GnRH Receptor Antagonist (CMS-D002)		Intended for uterine fibroids	No “flare-up effect”, rapidly and competitively binding to the GnRH receptor and blocking its activation; providing reversible effect with gonadal function expected to recover after drug withdrawal
GLP-1R/GCGR Dual Agonist (CMS-D005)		Intended for overweight/obesity	Expected to reduce weight through appetite suppression, and enhance lipolysis, especially the reduction of liver fat
Cardiac Myosin Inhibitor (CMS-D003)		Intended for hypertrophic cardiomyopathy	Demonstrating a short half-life and minimal risk of drug interactions; providing a potentially superior and safer oral therapy
Complement Factor B Inhibitor (CMS-D017)		Intended for paroxysmal nocturnal hemoglobinuria	Alleviating complement dysregulation-related diseases by blocking alternative pathway abnormal activation; providing a potentially superior and more convenient oral therapy
		Intended for complement-mediated kidney disease
		Intended for age-related macular degeneration
A siRNA therapy targeting and inhibiting INHBE (CMS-D008)		Intended for overweight/obesity	Targeting and reducing the hepatic expression of INHBE gene and reducing fat accumulation effectively, demonstrating the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass
> 20 Self-developed Innovative Drugs

* CMS’s rights are stated by Rights Authorized Region. CMS has NO development, commercialization or other product rights in unauthorized regions.
** Ruxolitinib phosphate cream has been approved for marketing in the EU for moderate AD indication in July 2026.
*** The Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for MG-K10 in Mainland China, Hong Kong, Macau, Taiwan Region and Singapore.
^# The rights authorized region of ZUNVEYL includes Asia (excluding Japan and the Middle East region) and other designated territories.
^## Taiwan Region is not included in the rights authorized region of ABP-671.
Updated as at 18 August 2026